SCHEMBL3702121

SCHEMBL3702121

COC(=O)C1CNCc2ccccc21

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 2/20 0.45
MEN1 O00255 1/20 0.45
CYP3A4 P08684 1/20 0.45
KMT2A Q03164 1/20 0.45
TAOK1 Q7L7X3 1/20 0.42
TAOK3 Q9H2K8 1/20 0.42
PIN1 Q13526 2/20 0.40
HTR2A P28223 2/20 0.39
MAPT P10636 2/20 0.36
SLC6A3 Q01959 1/20 0.35
POLB P06746 1/20 0.35
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
CYP1A2 P05177 1/20 0.35
GAA P10253 1/20 0.35
CYP2C9 P11712 1/20 0.35
HPGD P15428 1/20 0.35
ALOX15 P16050 1/20 0.35
CYP2C19 P33261 1/20 0.35
HSD17B10 Q99714 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL27924558 0.98 CYP2D6 (0.44) CYP2D6MEN1CYP3A4KMT2ATAOK1
Sulfuric Acid SCHEMBL20561327 0.94 CYP2D6 (0.41) CYP2D6MEN1CYP3A4KMT2ATAOK1
SCHEMBL7452682 0.84 MEN1 (0.42) CYP2D6MEN1CYP3A4KMT2ATAOK1
SCHEMBL17583845 0.81 AKR1C3 (0.39)
SCHEMBL1338359 0.80 MEN1 (0.54) CYP2D6MEN1CYP3A4KMT2ATAOK1
SCHEMBL29595365 0.80 MEN1 (0.54) CYP2D6MEN1CYP3A4KMT2ATAOK1
SCHEMBL30932922 0.80 HTR2A (0.46) HTR2AHTR2CHTR2B
SCHEMBL31730718 0.80 PNMT (0.36) HTR2ASLC6A3ALDH1A1HTR2CHTR2B
Acetic Acid SCHEMBL27449656 0.79 MEN1 (0.50) CYP2D6MEN1CYP3A4KMT2ATAOK1
SCHEMBL27909506 0.79 HDAC4 (0.50) CYP2D6MEN1CYP3A4KMT2ATAOK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11833162-B2 Macrocyclic derivatives, process for preparing same and pharmaceutical compositions containing same LES LABORATOIRES SERVIER (FR) 2023-12-05 US disclosed
EP-3700911-B1 NOVEL MACROCYCLIC DERIVATIVES, PROCESS FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME SERVIER LAB (FR) 2023-09-06 EP disclosed
EP-3700911-A1 NOVEL MACROCYCLIC DERIVATIVES, PROCESS FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME Les Laboratoires Servier SAS (FR) 2020-09-02 EP disclosed
US-20200253993-A1 NOVEL MACROCYCLIC DERIVATIVES, PROCESS FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME LES LABORATOIRES SERVIER (FR) 2020-08-13 US disclosed
CN-111511750-A Novel macrocyclic derivatives, process for their preparation and pharmaceutical compositions containing them 法国施维雅药厂 2020-08-07 CN disclosed
US-10688080-B2 Compositions, methods of use, and methods of treatment UNIVERSITY OF SOUTH FLORIDA (US) 2020-06-23 US disclosed
WO-2019242599-A1 TETRAHYDRO ISOQUINOLINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF 浙江海正药业股份有限公司 2019-12-26 WO disclosed
CN-109562168-A anti-CD 98 antibodies and antibody drug conjugates 艾伯维公司 2019-04-02 CN disclosed
WO-2018047983-A1 INDANE DERIVATIVES USEFUL AS MODULATORS OF MGLUR7 TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-03-15 WO disclosed
CN-103732589-B Can be used as the sulphonamide of the replacement of anti-apoptotic BCL inhibitor BRISTOL-MYERS SQUIBB CO. (US) 2016-03-30 CN disclosed
CN-103957711-A use of substituted isoquinolinones, isoquinolinediones, isoquinolinetriones and dihydroisoquinolinones or their respective salts as active agents against abiotic stress in plants BAYER IP GMBH 2014-07-30 CN disclosed
CN-102378574-B Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof TRANSTECH PHARMA INC 2013-11-20 CN disclosed
US-20120122854-A1 Carbocyclic Fused Cyclic Amines BOEHRINGER MARKUS (CH) 2012-05-17 US disclosed
EP-1948639-A2 NOVEL CARBOCYCLIC FUSED CYCLIC AMINES F. Hoffmann-la Roche AG (CH) 2008-07-30 EP disclosed
WO-2007054453-A2 CARBOCYCLIC FUSED CYCLIC AMINES AS INHIBITORS OF THE COAGULATION FACTOR XA F. HOFFMANN-LA ROCHE AG (CH) 2007-05-18 WO disclosed
US-20070112012-A1 Carbocyclic fused cyclic amines F. HOFFMANN-LA ROCHE AG (CH) 2007-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070112012-A1 Carbocyclic fused cyclic amines F12, F11, F2 CYP2D6 942/4885MEN1 191/4885CYP3A4 398/4885
US-11833162-B2 Macrocyclic derivatives, process for preparing same and pharmaceutical compositions containing same C1R, F12, RDX CYP2D6 123/4885MEN1 592/4885CYP3A4 38/4885
US-10688080-B2 Compositions, methods of use, and methods of treatment LIPA, LCT, GAA CYP2D6 607/4885MEN1 3198/4885CYP3A4 722/4885
US-20120122854-A1 Carbocyclic Fused Cyclic Amines F12, F11, F2 CYP2D6 942/4885MEN1 191/4885CYP3A4 398/4885
US-20200253993-A1 NOVEL MACROCYCLIC DERIVATIVES, PROCESS FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME C1R, RDX, F12 CYP2D6 183/4885MEN1 755/4885CYP3A4 59/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.